Cardiology, Central South University, Third Xiangya Hospital, Changsha, Hunan, China.
Cardiology, Central South University, Third Xiangya Hospital, Changsha, Hunan, China
Postgrad Med J. 2020 Dec;96(1142):742-746. doi: 10.1136/postgradmedj-2019-137008. Epub 2020 Feb 11.
We are currently faced with an increasing burden of cardiovascular disease in China and the inadequacy of the application of guidelines in clinical practice. In the past decade, China has been strengthening the healthcare system, but it still lacked a national performance measurement system and an appropriate quality improvement strategy. Therefore, in order to improve the implementation of guideline recommendations in clinical practice, China has learnt from the successful experience of Get With The Guidelines project in 2014. Under the guidance of the Medical and Health Hospital of the National Health and Family Planning Commission, the Chinese Society of Cardiology and the American Heart Association jointly launched the Improving Care for Cardiovascular Disease in China (CCC) project. The project team provided an analysis report on the completion of key medical quality evaluation indicators of each hospital every month, supplied guidance through education, training, experience exchange and on-site investigation for problems, and certified hospitals with outstanding performance and obvious progress. The circle pattern, including evaluation, training, improvement and re-evaluation, will boost the guidelines compliance on clinical practice in China and improve the quality of medical services.
This study was conducted in a centre of the Third Xiangya Hospital of Central South University. It included patients with ACS from December 2009 to December 2011 (n=225), patients with ACS in the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome project coming from the Third Xiangya Hospital of Central South University (n=665), 12 hospitals in Hunan Province (n=4333) and 150 hospitals in China (n=63 641) from November 2014 to April 2017. It assessed the situation of drug therapy, hospitalisation day, mortality during hospitalisation, median of door-to-needle (D-to-N) time and median of door-to-balloon (D-to-B) time of patients with ST-segment elevation myocardial infarction (STEMI), the proportion of D-to-N within 30 min and D-to-B within 90 min, and the proportion of reperfusion therapy. Patients with ACS from the centre from November 2014 to April 2017 were divided into five groups (every 6 months as a group according to time). The study observed change trends in all the above-mentioned indexes.
Compared with before participating in the CCC project, there were increases after participating in the CCC project in the drug usage rates of aspirin, P2Y12 inhibitor (clopidogrel or ticagrelor), β-blocker, statin and angiotensin converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB). Hospitalisation day and mortality during hospitalisation were shortened. D-to-N and D-to-B times of patients with STEMI were shorter. Compared with Hunan Province and China, the drug usage rates were higher; hospitalisation day and D-to-N time were shorter; D-to-B time was longer; and the proportion of reperfusion therapy was higher. The trend of drug usage rates was on the rise. There was no significant change in the hospitalisation day and D-to-N and D-to-B times. The mortality during hospitalisation showed a downward trend. The proportion of D-to-N within 90 min and reperfusion therapy showed upward trends.
Quality of care for patients with ACS improved over time in the CCC project, including taking medicine following the guidelines, increased use of reperfusion therapy and faster time to treatment. Although overall mortality has improved, we also should attach importance to high-risk patients. The influence of the CCC project, which is based on guidelines on prognosis of ACS in the centre, presents an important clinical implication that it is necessary to enhance adherence to the guidelines in the treatment of ACS.
目前中国面临心血管疾病负担日益加重的问题,同时临床实践中指南应用不足。过去十年,中国一直在加强医疗体系建设,但仍缺乏全国性的绩效衡量体系和适当的质量改进策略。因此,为了提高临床实践中指南建议的实施,中国借鉴了 2014 年 Get With The Guidelines 项目的成功经验。在中国国家卫生健康委员会医疗管理服务指导中心、中华医学会心血管病学分会和美国心脏协会的指导下,联合启动了“改善中国心血管疾病管理项目”(CCC)。项目组每月对每家医院的关键医疗质量评估指标完成情况进行分析报告,针对问题提供教育、培训、经验交流和现场调查指导,并对表现出色且明显进步的医院进行认证。这种包括评估、培训、改进和再评估的循环模式将促进中国临床实践中指南的依从性,提高医疗服务质量。
本研究在中南大学湘雅三医院中心进行,纳入了 2009 年 12 月至 2011 年 12 月的急性冠状动脉综合征(ACS)患者(n=225)、来自中南大学湘雅三医院的 CCC 项目 ACS 患者(n=665)、湖南省的 12 家医院(n=4333)和全国的 150 家医院(n=63641)。评估了 ST 段抬高型心肌梗死(STEMI)患者的药物治疗、住院日、住院期间死亡率、门到针(D-to-N)时间中位数和门到球囊(D-to-B)时间中位数、30 分钟内 D-to-N 比例和 90 分钟内 D-to-B 比例以及再灌注治疗比例。2014 年 11 月至 2017 年 4 月在中心的 ACS 患者分为五组(根据时间每 6 个月一组)。观察了所有上述指标的变化趋势。
与参加 CCC 项目前相比,参加 CCC 项目后,阿司匹林、P2Y12 抑制剂(氯吡格雷或替格瑞洛)、β受体阻滞剂、他汀类药物和血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂(ACEI/ARB)的使用率增加。住院日和住院期间死亡率缩短。STEMI 患者的 D-to-N 和 D-to-B 时间缩短。与湖南省和全国相比,药物使用率更高,住院日和 D-to-N 时间更短,D-to-B 时间更长,再灌注治疗比例更高。药物使用率呈上升趋势。住院日和 D-to-N、D-to-B 时间无明显变化。住院期间死亡率呈下降趋势。D-to-N 90 分钟内和再灌注治疗比例呈上升趋势。
在 CCC 项目中,ACS 患者的治疗质量随着时间的推移而提高,包括遵循指南进行药物治疗、增加再灌注治疗的使用和更快的治疗时间。尽管整体死亡率有所改善,但我们也应关注高危患者。基于中心 ACS 预后指南的 CCC 项目的影响提出了一个重要的临床意义,即有必要加强 ACS 治疗中的指南依从性。